Published in Gynecol Oncol on April 27, 2010
Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst (2012) 1.07
Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer. Gynecol Oncol (2011) 0.95
HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer. Oncotarget (2014) 0.91
Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy. Ther Adv Med Oncol (2014) 0.85
Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res (2014) 0.85
The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years. Front Oncol (2016) 0.79
Risk-scoring model for prediction of non-home discharge in epithelial ovarian cancer patients. J Am Coll Surg (2013) 0.78
Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study. Int J Gynecol Cancer (2017) 0.75
Evaluation of serum levels of sCD30L ligand in patients with ovarian cancer in terms of selected clinico-pathological factors. Contemp Oncol (Pozn) (2013) 0.75
The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer (2010) 2.13
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest (2009) 1.87
Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (2009) 1.87
Trends in treatment of advanced epithelial ovarian cancer in the Medicare population. Gynecol Oncol (2011) 1.77
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol (2009) 1.77
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol (2011) 1.74
Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol (2005) 1.72
Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol (2002) 1.72
Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer (2008) 1.53
Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol (2007) 1.49
Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study. Cancer (2011) 1.47
An evaluation of cervical cancer in women age sixty and over. Gynecol Oncol (2008) 1.43
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol (2006) 1.31
Epithelial ovarian cancer. J Natl Compr Canc Netw (2011) 1.16
Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol (2008) 1.15
Ovarian cancer, version 2.2013. J Natl Compr Canc Netw (2013) 1.13
Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer (2009) 1.12
Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol (2006) 1.12
Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations? Ann Intern Med (2012) 1.12
Self-assessment of resident surgical skills: is it feasible? Am J Obstet Gynecol (2005) 1.11
Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer (2011) 1.11
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.06
Surgical outcomes in gynecologic oncology in the era of robotics: analysis of first 1000 cases. Am J Obstet Gynecol (2011) 1.06
MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer (2010) 1.05
Patterns of spread and recurrence of sex cord-stromal tumors of the ovary. Gynecol Oncol (2011) 1.04
Advances in vulvar and vaginal cancer treatment. Gynecol Oncol (2010) 0.99
Factors affecting risk of mortality in women with vaginal cancer. Obstet Gynecol (2009) 0.99
A new curriculum for hysteroscopy training as demonstrated by an objective structured assessment of technical skills (OSATS). Am J Obstet Gynecol (2005) 0.97
A six-year study of surgical teaching and skills evaluation for obstetric/gynecologic residents in porcine and inanimate surgical models. Am J Obstet Gynecol (2005) 0.96
Dangerous combinations: Ingestible CAM supplement use during chemotherapy in patients with ovarian cancer. J Altern Complement Med (2013) 0.96
Pelvic exenteration in the age of modern chemoradiation. Gynecol Oncol (2011) 0.95
Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer. Gynecol Oncol (2011) 0.95
Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. Clin Immunol (2007) 0.93
Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer (2007) 0.92
Identification of ovarian cancer symptoms in health insurance claims data. J Womens Health (Larchmt) (2010) 0.91
Uterine papillary serous carcinoma: what have we learned over the past quarter century? Gynecol Oncol (2005) 0.89
Glassy cell carcinoma of the cervix revisited. Gynecol Oncol (2002) 0.88
HoxA10 influences protein ubiquitination by activating transcription of ARIH2, the gene encoding Triad1. J Biol Chem (2011) 0.87
Risk of epithelial ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally acting medications. Cancer Causes Control (2002) 0.86
Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol Oncol (2006) 0.85
Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol (2011) 0.85
Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the Puget Sound Oncology Consortium. Gynecol Oncol (2005) 0.83
Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. Gynecol Oncol (2009) 0.82
Value of symptom-triggered diagnostic evaluation for ovarian cancer. Obstet Gynecol (2014) 0.82
FOXP3+ regulatory T-cells are abundant in vulvar Paget's disease and are associated with recurrence. Gynecol Oncol (2011) 0.82
Involvement in decision-making about treatment and ovarian cancer survivor quality of life. Gynecol Oncol (2011) 0.81
Microparticles from ovarian carcinomas are shed into ascites and promote cell migration. Int J Gynecol Cancer (2012) 0.81
Reporting of quality measures in gynecologic oncology programs at Prospective Payment System (PPS)-Exempt Cancer Hospitals: an early glimpse into a challenging initiative. Gynecol Oncol (2013) 0.80
Suicide in women with gynecologic cancer. Gynecol Oncol (2011) 0.80
The significance of psammoma bodies in screening cervical cytologic smears. Am J Obstet Gynecol (2003) 0.80
The abandoned radical hysterectomy for cervical cancer: clinical predictors and outcomes. Obstet Gynecol Int (2010) 0.80
The temporal stability of the Symptom Index among women at high-risk for ovarian cancer. Gynecol Oncol (2009) 0.79
Surgical education: what role should gynecologic oncologists play? Gynecol Oncol (2008) 0.79
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers. Neoplasia (2010) 0.79
Guideline-inconsistent breast cancer screening for women over 50: a vignette-based survey. J Gen Intern Med (2013) 0.79
Saphenous vein sparing during inguinal lymphadenectomy to reduce morbidity in patients with vulvar carcinoma. Gynecol Oncol (2005) 0.78
Accuracy of ovarian and colon cancer risk assessments by U.S. physicians. J Gen Intern Med (2014) 0.77
A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study. Int J Gynecol Cancer (2015) 0.77
Training the next generation of minimally invasive surgeons. J Minim Invasive Gynecol (2009) 0.77
Evaluation of postoperative fever: usefulness and cost-effectiveness of routine workup. Am J Obstet Gynecol (2003) 0.77
Nonrecommended breast and colorectal cancer screening for young women: a vignette-based survey. Am J Prev Med (2012) 0.77
Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol (2013) 0.75
Disparities in treatment and survival between African American and White women with vaginal cancer. Gynecol Oncol (2011) 0.75
Cyclooxygenase (COX)-2 and granulosa cell apoptosis in vitro. J Assist Reprod Genet (2002) 0.75
Adverse events associated with complementary and alternative medicine use in ovarian cancer patients. Integr Cancer Ther (2013) 0.75
Angiogenic alterations associated with circulating neoplastic DNA in ovarian carcinoma. Transl Oncol (2012) 0.75
Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers. Cancer Genet Cytogenet (2008) 0.75
Delayed hemorrhage after cervical conization unmasking severe factor XI deficiency. Obstet Gynecol (2004) 0.75
We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies. Gynecol Oncol (2013) 0.75
'Lower anti-drug antibodies with etanercept biosimilar: can Ctrough explain the differences?'. Ann Rheum Dis (2016) 0.75
Evaluation of a Validated Biomarker Test in Combination With a Symptom Index to Predict Ovarian Malignancy. Int J Gynecol Cancer (2016) 0.75
Surgery for ovarian cancer: rationale and guidelines. J Natl Compr Canc Netw (2004) 0.75
Quality measures in gynecologic cancers: what and when? Gynecol Oncol (2008) 0.75
Surgical education for gynecologic oncologists. Gynecol Oncol (2009) 0.75